Thus, a neprilysin inhibitor cannot be used to treat AF in monotherapy because activation of angiotensin II signaling pathways limits its beneficial effect in a feedback increase of NP levels (Richards et al., 1993). This evidence concerns the gene AGT and atrial fibrillation.